Modeling the profound systemic and immunological dysregulation of clinical sepsis requires a highly translatable, polymicrobial in vivo platform. At BioLegacy, we provide this definitive assessment using the gold-standard cecal ligation and puncture (CLP) model, which accurately recapitulates the complex pathophysiology of human abdominal sepsis. Our expertise in this surgically-induced model allows for a robust evaluation of your therapeutic’s ability to modulate the cytokine cascade, preserve organ function, and ultimately improve survival, delivering the pivotal data your program requires.
While standard infection models are the foundation of anti-infective research, the true quality of the data is driven by the surrounding analytical and scientific expertise. At BioLegacy, our strategic advantage lies in this integrated support. Our studies are conducted by a highly experienced team within a secure BSL-2 environment, ensuring data integrity and precise clinical monitoring, while our in-house bioanalytical platforms provide a deep, quantitative understanding of the host-pathogen interaction. By seamlessly combining bacterial load quantification with in-depth immunophenotyping, cytokine profiling, and integrated PK/PD analysis, we deliver a multi-faceted, mechanistic data package that clearly differentiates your compound’s efficacy.
